Loading...
P01.110 Elderly patients >65years of age with newly diagnosed Glioblastoma multiforme gain life time from treatment with Tumor Treating Fields and Temozolomide
BACKGROUND: Glioblastoma (GBM) is the most aggressive form of primary brain cancer in adults. The EF-14 trial was the first randomized controlled trial to report a survival benefit for newly diagnosed GBM patients in more than a decade with a survival rate greater than 10% at 5-years. A post hoc sub...
Saved in:
| Published in: | Neuro Oncol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Oxford University Press
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6144654/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.152 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|